Kremlin bicêtre
Bicêtre, 94275, France
NCT Number: NCT02110797
Based on our clinical observations, many girls with RETT syndrome, a severe neuro-developmental encephalopathy, suffer from osteoporosis which can appear at a very early age (before age 10) and can lead to fractures, pain and a limitation in mobility. Few epidemiological studies have estimated the frequency of osteoporosis in girls with RETT syndrome and showed that they are more exposed then children with other neuro-developmental diseases with a same degree of neurological handicap. However, the mechanisms that lead to early osteoporosis in RETT syndrome remain unknown. Mutations in the MECP2 gene are found in 95% of RETT patients and preliminary experimental studies have shown that this can lead to abnormal expression of the gene that codes for osteoprotegerin, a protein implicated in bone remodelling by interacting with RANK-ligand.
In order to identify risk factors of osteoporosis in RETT syndrome and to understand the pathophysiological mechanisms the study protocol includes:
1. Clinical evaluation of bone health (history of bone fractures, pain, nutritional status, pubertal stage, daily caloric/calcium intake, anti-epileptic drugs, walking ability, vitamin D satus) 2. evaluation of the mineral density at the lumber spine using DEXA 3. measuring concentrations of osteoprotegerin and RANK-ligand
Looking for future studies?
Notify Me5 year–45 year
Female
Interventional
Not applicable
Bicêtre, 94275, France
Based on our clinical observations, many girls with RETT syndrome, a severe neuro-developmental encephalopathy, suffer from osteoporosis which can appear at a very early age (before age 10) and can lead to fractures, pain and a limitation in mobility. Few epidemiological studies have estimated the frequency of osteoporosis in girls with RETT syndrome and showed that they are more exposed to osteoporosis then children with other neuro-developmental diseases with a same degree of neurological handicap. However, the mechanisms that lead to early osteoporosis in RETT syndrome remain unknown.
Mutations in the MECP2 gene are found in 95% of RETT patients. Preliminary experimental studies on the transcriptional consequences of MECP2 mutations showed that the expression of 13 genes were significantly dysregulated and one of them is the gene that codes for osteoprotegerin, a soluble receptor that binds to RANK-ligand. RANK-ligand is an osteoclastic differentiation factor expressed by osteoblasts.
In order to identify risk factors of osteoporosis in RETT syndrome and to understand the pathophysiological mechanisms the study protocol includes:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day 0
Correlation between clinical/biological risk factors and mineral density and osteoporosis in RETT patients
Time frame: Day 0
RANK-ligand and osteoprotegerin concentrations
Assistance Publique - Hôpitaux de Paris
Other
Osteoporosis in RETT Syndrome. Understanding the Mechanisms and Identification of Biomarkers.
Acronym: OSRETT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07257978
Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Clayton, Victoria, Australia
View Trial DetailsNCT07493096
22q11 Deletion Syndrome, 22q11.2 Deletion Syndrome
The Woodlands, Texas, United States
View Trial DetailsNCT07430046
Cognition Disorders, Cognitive Dysfunction
Genova, Italy
View Trial DetailsNCT06739434
RETT Syndrome With Proven MECP2 Mutation
Shanghai, Shanghai Municipality, China
View Trial Details